Neuropeptidases

Handbook of Neurochemistry and Molecular Neurobiology: Neural Protein Metabolism and Function

Volumn , Issue , 2007, Pages 625-651

  Hui, K S ^a,b  

^a NATHAN S KLINE INSTITUTE FOR PSYCHIATRIC RESEARCH   (United States)

^b NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 35848969929     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-0-387-30379-6_21     Document Type: Chapter

References (196)

1. Acher R, Chauvet J, Rouille Y. 2002. Dynamic processing of neuropeptides: Sequential conformation shaping of neurohypophysial preprohormones during intraneuronal secretory transport. J Mol Neurosci 18:223-228.
2. Alvarez R, Alvarez V, Lahoz CH, Martinez C, Pena J, et al. 1999. Angiotensin-converting enzyme and endothelial nitric oxide synthase DNA polymorphisms and late-onset Alzheimer's disease. J Neurol Neurosurg Psychiatry 67:733-736.
3. Azaryan AV, Hook VYH. 1994a. Distinct properties of "prohormone thiol pretease" (PTP) compared to cathepsins B, L, and H: Evidence for PTP as a novel cysteine protease. Arch Biochem Biophys 314:170-177.
4. Azaryan AV, Hook VYH. 1994b. Unique cleavage site specificity of "prohormone thiol protease" related to proenkephalin processing. FEBS Lett 342:197-202.
5. Azaryan AV, Krieger TK, Hook VYH. 1995a. Characteristics of the candidate prohormone processing proteases, PC2 and PC1/3, from bovine adrenal medulla chromaffin granules. J Biol Chem 270:8201-8208.
6. Azaryan TK, Mende-Mueller L, Hook VYH. 1992. Prohormone thiol protease and enkephalin precursor processing: Cleavage at dibasic and monobasic sites. J Neurochem 59:26-31.
7. Azaryan AV, Schiller MR, Hook VYH. 1995b. Chromaffin granule aspartic proteinase processes recombinant proopiomelanocortin (POMC). Biochem Biophys Res Comm 215:937-944.
8. Azaryan AV, Schiller M, Mende-Mueller L, Hook VYH. 1995c. Characteristics of the chromaffin granules aspartic proteinase involves in proenkephalin processing. J Neurochem 65:1771-1779.
9. Barnes K, Turner AJ, Kenny AJ. 1988. Electron microscopic immunocytochemistry of pig brain shows that endopeptidase 24.11 is localized in neuronal membranes. Neurosci Lett 94:64-69.
10. Bauer WO, Nanda I, Beck G, Schmid M, Jakob F. 2001. Human puromycin-sensitive aminopeptidase: Cloning of 3'-UTR, evidence for a polymorphism at a.a.140 and refined chromosomal localization to 17q21. Cytogenet Cell Genet 92:221-4.
11. Beal MF, Martin JB. 1986. Neuropeptides in neurological disease. Ann Neurol 20:547-65.
12. Beal MF, Uhl G, Mazurek MF, Kowall N, Martin JB. 1986. Somatostatin: Alterations in the central nervous system in neurological diseases. Res Publ Assoc Res Nerv Ment Dis 64:215-57.
13. Bernardini F, Warburton MJ. 2001. The substrate range of tripeptidyl peptidase I. Eur J Paediatr Neurol 5A:69-72.
14. Bernardini F, Warburton MJ. 2002. Lysosomal degradation of cholecystokinin-(29-33)-amide in mouse brain is dependent on tripeptidyl peptidase-I: Implications for the degradation and storage of peptides in classical late-infantile neuronal ceroid lipofuscinosis. Biochem J 366:521-529.
15. Bloom F, Segal D, Ling N, Guillemin R. 1976. Endorphins: Profound behavioral effects in rats suggest new etiological factors in mental illness. Science 194:630-632.
16. Boileu G, Barbeau C, Jeannotte L, Chretien M, Drouin J. 1983. Complete structure of the porcine proopiomelanocortin mRNA derived from the nucleotide sequence of cloned cDNA. Nucleic Acids Res 11:8063-8071.
17. Bolumar T, Sanz Y, Aristoy MC, Toldra F. 2003. Purification and properties of an arginyl aminopeptidase from Debaryomyces hansenii. Int J Food Microbiol 86:141-151.
18. Brands B, Thornhill JB, Hirst M, Gowdey CW. 1979. Suppression of food intake and body weight gain by naloxone in rats. Life Sci 24:1773-1778.
19. Breslin HJ, Miskowski TA, Kukla MJ, De Winter HL, Somers MV, et al. 2003. Tripeptidyl-peptidase II (TPP II) inhibitory activity of (S)-2, 3-dihydro-2-(1H-imidazol-2-yl)-1H-indoles, a systematic SAR evaluation. Part 2. Bioorg Med Chem Lett 13:4467-4471.
20. Bryce GF, Rabin BR. 1964. The function of the metal ion in leucine aminopeptidase and the mechanism of action of the enzyme. Biochem J 90:513-518.
21. Bzdega T, Chin H, Kim H, Jung HH, Kozak CA, et al. 1993. Regional expression and chromosomal localization of the d opiate receptor gene. Proc Natl Acad Sci USA 90:9305-9309.
22. Bzdega T, Turi T, Wroblewska B, She D, Chung HS, et al. 1997. Molecular cloning of a peptidase against N-acetylaspartylglutamate from a rat hippocampal cDNA library. J Neurochem 69:2270-2277.
23. Cahill CM, Morinville A, Lee MC, Vincent JP, Collier B, et al. 2001. Prolonged morphine treatment targets d opioid receptors to neuronal plasma membranes and enhances d-mediated antinociception. J Neurocsci 21:7598-7607.
24. Cai Z, Lin S, Rhodes PG. 2002. Neuroprotective effects of N-acetylaspartylglutamate in a neonatal rat model of hypoxia-ischemia. Eur J Pharmacol 437:139-145.
25. Chai SY, Mendelsohn FAO. 1995. Autoradiographic techniques to map angiotensin-converting enzyme in brain and other tissues. Peptidases and neuropeptide processing. Smith AI, editor. New York: Academic Press; pp. 383-398.
26. Chen Y, Mestek A, Liu J, Hurley JA, Yu L. 1993. Molecular cloning and functional expression of a m-opioid receptor from rat brain. Mol Pharmacol 44:8-12.
27. Chipkin RE, Berger JG, Billard W, Iorio LC, Chapman R, et al. 1988. Pharmacology of SCH 34826, an orally active enkephalinase inhibitor analgesic. J Pharmacol Exp Ther 245:829-838.
28. Civelli O, Douglass J, Goldstein A, Herbert E. 1985. Sequence and expression of the rat prodynorphin gene. Proc Natl Acad Sci USA 82:4291-4295.
29. Congia S, Tronci S, Ledda M, Porcella A, Coppola G. 1991. Low doses of TRH in amyotrophic lateral sclerosis and in other neurological diseases. Ital J Neurol Sci 12:193-198.
30. Constam DB, Tobler AR, Rensing-Ehl A, Kemler I, Hersh LB, et al. 1995. Puromycin-sensitive aminopeptidase: Sequence analysis, expression, and functional characterization. J Biol Chem 270:26931-26939.
31. Coyle JT. 1997. The nagging question of the function of N-acetylaspartylglutamate. Neurobiol Dis 4:231-238.
32. Cramer H, Rosler N, Rissler K, Gagnieu MC, Renaud B. 1988. Cerebrospinal fluid immunoreactive substance P and somatostatin in neurological patients with peripheral and spinal cord disease. Neuropeptides 12:119-124.
33. De Gandarias JM, Irazusta J, Gil J, Fernandez D, Varona A, et al. 1999. Ontogeny of puromycin-sensitive and insensitive aminopeptidase activities in several subcellular fractions of the rat brain. Brain Res Bull 50:283-290.
34. De La Baume S, Yi CC, Schwartz J-C, Marcais-Collado H, Costentin J. 1983. Participation of both "enkephalinase" and aminopeptidase activities in the metabolism of endogenous enkephalins. Neuroscience 8:143-151.
35. Delgado M, Ganea D. 2003. Vasoactive intestinal peptide prevents activated microglia-induced neurodegeneration under inflammatory conditions: Potential therapeutic role in brain trauma. FASEB J 17:1922-1924.
36. De Wied D, Bohus B, van Ree JM, Urban I. 1978. Behavioral and electrophysiological effects of peptides related to lipotropin (βLPH). J Pharmacol Exp Ther 204:570-580.
37. Dhanvantari S, Arnaoutova I, Snell CR, Steinbach PJ, Hammond K, et al. 2002. Carboxypeptidase E, a prohormone sorting receptor, is anchored to secretory granules via a C-terminal transmembrane insertion. Biochemistry 41:52-60.
38. Diez M, Koistinaho J, DeArmond SJ, Camerino AP, Groth D, et al. 1996. Aberrant induction of neuropeptide Y mRNA in hippocampal CA3 pyramidal neurons in scrapie-infected mice. Neuroreport 7:1887-1892.
39. Docherty AJ, Crabbe T, O'Connell JP, Groom CR. 2003. Proteases as drug targets. Biochem Soc Symp 70:147-161.
40. Du PG, Kato S, Li YH, Maeda T, Yamane T, et al. 2001. Rat tripeptidyl peptidase I: Molecular cloning, functional expression, tissue localization, and enzymatic characterization. Biol Chem 382:1715-1725.
41. Dyer SH, Slaughter CA, Orth K, Moomaw CR, Hersh LB. 1990. Comparison of the soluble and membrane-bound forms of the puromycin-sensitive enkephalin-degrading aminopeptidases from rat. J Neurochem 54:547-554.
42. Ehlers MR, Riordan JF. 1991. Angiotensin-converting enzyme: Zinc- and inhibitor-binding stoichiometrics of the somatic and testis isozymes. Biochemistry 3029:7118-7126.
43. Eisenstein EM, Altman HJ, Barraco DA, Barraco RA, Lovell KL. 1983. Brain protein synthesis and memory: the use of antibiotic probes. Fed Proc 42:3080-3085.
44. Facchinetti P, Rose C, Rostaing P, Triller A, Schwartz JC. 1999. Immunolocalization of tripeptidyl peptidase II, a cholecystokinin-inactivating enzyme, in rat brain. Neuroscience 88:1225-1240.
45. Frenk H, McCarty BC, Lieberkind JC. 1978. Different brain areas mediate the analgesic and epileptic properties of enkephalin. Science 200:335-337.
46. Fricker LD. 1991. Peptide processing exopeptidase: Amino and carboxypeptidases involved in peptide biosynthesis. Peptide biosynthesis and processing. Fricker LD, editor. Boca Raton: CRC Press; pp. 199-229.
47. Fricker LD, Das B, Angeletti RH. 1990. Identification of the pH-dependent membrane anchor of carboxypeptidase E (EC 3.4.17.10). J Biol Chem 265:2476-2482.
48. Fujiwara K, Matsumoto E, Kitagawa T, Tsuru D. 1982. N-acarbobenzoxy pyroglutamyl diazomethyl ketone as active site-directed inhibitor for pyroglutamyl peptidase. Biochim Biophys Acta 702:149-154.
49. Gainer H, Russell JT, Loh YP. 1984. An aminopeptidase activity in bovine pituitary secretory vesicles that cleaves the N-terminal arginine from beta-lipotropin 60-65. FEBS Lett 175:135-139.
50. Ghadge GD, Slusher BS, Bodner A, Canto MD, Wozniak K, et al. 2003. Glutamate carboxypeptidase II inhibition protects motor neurons from death in familial amyotrophic lateral sclerosis models. Proc Natl Acad Sci USA 100:9554-9559.
51. Gilmore W, Moradzadeh DS. 1993. βendorphin protects mice from neurological disease induced by the murine coronavirus MHV-JHM. J Neuroimmunol 48:81-90.
52. Gispen WH, Hamers FP, Vecht CJ, Jennekens FG, Neyt JP. 1992. ACTH/MSH like peptides in the treatment of cisplatin neuropathy. J Steroid Biochem Mol Biol 43:179-183.
53. Golabek AA, Kida E, Walus M, Wujek P, Mehta P, et al. 2003. Biosynthesis, glycosylation, and enzymatic processing in vivo of human tripeptidyl peptidase I. J Biol Chem 278:7135-7145.
54. Goodman RR, Fricker LD, Snyder SH. 1983. Enkephalins. Brain peptides. Krieger DT, Brownstein MJ, Martin JB, editors. New York: John Wiley & Sons; pp. 827-849.
55. Graf L, Nagy A, Lajtha A. 1982. Enkephalin-hydrolyzing peptidases of rat brain membrane: are they topographically/functionally coupled to opiate receptors? Life Sci 31:1861-1865.
56. Gubler U, Seeburg P, Hoffman BJ, Gage LP, Udenfriend S. 1982. Molecular cloning establishes proenkephalin as precursor of enkephalin-containing peptides. Nature 295:206-208.
57. Halban PA. 1980. Intracellular degradation of insulin stores by rat pancreatic islets in vitro. An alternative pathway for homeostasis of pancreatic insulin content. J Biol Chem 255:6003-6006.
58. Herman ZS, Strachura Z, Laskawiec G, Kowalski J, Obuchowicz E. 1985. Antinociceptive effects of puromycin and bacitracin. Pol J Pharmacol 37:133-140.
59. Holaday JH, Loh HH, Li CH. 1978. Unique behavioral effects of βendorphin and their relationship to thermoregulation and hypothalamic function. Life Sci 22:1525-1536.
60. 125I- (Met) enkephalin in bovine adrenal medullary chromaffin granules. FEBS Lett 171:212-218.
61. Hook VYH, Eiden LE. 1985. Selective regulation of carboxypeptidase peptide hormone processing enzyme during enkephalin biosynthesis in cultured bovine adrenomedullary chromaffin cells. J Biol Chem 260:5991-5997.
62. Hook VYH, Reisine TD. 2001. Endorphin. Encyclopedia of molecular medicine. Creighton TE, editor. NJ: John Wiley & Sons, pp. 1161-1164.
63. Hook VYH, Yasothornsrikul S. 1998. Carboxypeptidase and aminopeptidase proteases in proneuropeptide processing. Proteolytic and cellular mechanisms in prohormone and proprotein processing. Hook VYH, editor. Austin, TX: Landes Bioscience Publishers; pp. 121-140.
64. Hook VYH, Azaryan AV, Hwang SR. 1994. Proteases and the emerging role of protease inhibitors in prohormone processing. FASEB J 8:1269-1278.
65. Hook VYH, Moran K, Kannan R, Kohn A, Lively MO, et al. 1997. High-level expression of the prohormone proenkephalin, proneuropeptide Y, proopiomelanocortin, and protachykinin for in vitro prohormone processing. Protein Expr Purif 10:80-88.
66. Hook VYH, Schiller MR, Azaryan AV. 1996. The processing proteases prohormone thiol protease, PC1/3 and PC2, and 70-kDa aspartic proteinase show preferences among proenkephalin, proneuropeptide Y, and proopiomelanocortin substrates. Arch Biochem Biophys 328:107-114.
67. Hooper NM, Turner AJ. 1988. Ectoenzymes of the kidney microvillar membrane. Aminopeptidase P is anchored by a glycosyl-phosphatidylinositol moiety. FEBS Lett 229:340-344.
68. Horsthemke B, Hamprecht B, Bauer K. 1983. Heterogeneous distribution of enkephalin-degrading peptidases between neuronal and glial cells. Biochem Biophys Res Comm 115:423-429.
69. Howell S, Murray H, Scott CS, Turner AJ, Kenny AJ. 1991. A highly sensitive ELISA for endopeptidase-24.11, the common acute lymphoblastic leukemia antigen (CALLA, CD-10), applicable to material of porcine and human origin. Biochem J 278:417-421.
70. Hu J, Miyatake F, Aizu Y, Nakagawa H, Nakamura S, et al. 1999. Angiotensin-converting enzyme genotype is associated with Alzheimer's disease in the Japanese population. Neurosci Lett 277:65-67.
71. Hui K-S. 1988. A novel dipeptidyl aminopeptidase in rat brain membranes: its isolation, purification, and characterization. J Biol Chem 263:6613-6618.
72. Hui K-S, Hui M. 1996. An automatic continuous-flow aminopeptidase detector and its applications. Anal Biochem 242:271-273.
73. Hui K-S, Lajtha A. 1983. Neuropeptidases. Handbook of neurochemistry, Vol. 4. Lajtha A, editor. New York: Plenum; 2nd ed. pp. 1-19.
74. Hui K-S, Gioannini T, Hui M, Simon EJ, Lajtha A. 1985. Opiate receptor-associated aminopeptidases degrade enkephalins. Neurochem Res 10:1047-1058.
75. Hui K-S, Graf L, Lajtha A. 1982. β-Endorphin inhibits metenkephalin breakdown by a brain aminopeptidase: Structure-activity relationships. Biochem Biophys Res Comm 105:1482-1487.
76. Hui K-S, Hui M, Banay-Schwartz M, DeGuzman T, Ling N, et al. 1983a. Enkephalin-containing polypeptides are potent inhibitors of enkephalin degradation. Peptides 4:639-646.
77. Hui K-S, Hui M, Lajtha A. 1983b. Properties of a brain membrane aminoenkephalinase: Inhibition studies. Neural membranes. Sun G, Bazan N, Wu J-Y, Porcellati G, Sun AY, editors. NJ: Humana Press; pp. 375-393.
78. 0-Met-enkephalin from bovine striatum. J Neurochem 63:1748-1756.
79. Hui K-S, Saito M, Hui M. 1998. A novel neuron-specific aminopeptidase in rat brain synaptosomes. Its identification, purification, and characterization. J Biol Chem 273:31053-31060.
80. Hui K-S, Wang YJ, Lajtha A. 1983c. Purification and characterization of an enkephalin aminopeptidase from rat brain membranes. Biochemistry 22:1062-1067.
81. Hui M, Hui K-S. 2003. Neuron-specific aminopeptidase and puromycin-sensitive aminopeptidase in rat brain development. Neurochem Res 28:855-860.
82. Hui M, Budai ED, Lajtha A, Palkovits M, Hui K-S. 1995. Changes in puromycin-sensitive aminopeptidases in postmortem schizophrenic brain regions. Neurochem Int 27:433-441.
83. Hwang SR, Ng SM, Steineckert B, Seidah NG, Hook VYH. 2000. Molecular cloning demonstrates structural features of homologous bovine prohormone convertases 1 and 2. DNA Cell Biol 19:409-419.
84. Irazusta J, Larrinaga G, Agirregoitia N, Varona A, Casis L. 2003. Effects of morphine administration and its withdrawal on rat brain aminopeptidase activities. Regul Pept 110:225-230.
85. Iribar MC, Montes J, Gonzalez Maldonado R, Peinado JM. 1998. Alanyl-aminopeptidase activity decreases in cerebrospinal fluid of Alzheimer patients. Dement Geriatr Cogn Disord 9:44-49.
86. Jacquet YF, Marks N. 1976. The C-fragment of β-lipotropin: an endogenous neuroleptic or antipsychotogen? Science 194:632-635.
87. Jankovic BD, Maric D. 1987. Enkephalins and autoimmunity: Differential effect of methionine-enkephalin on experimental allergic encephalomyelitis in Wistar and Lewis rats. J Neurosci Res 18:88-94.
88. Johnson GD, Hersh LB. 1990. Studies on the subsite specificity of the rat brain puromycin-sensitive aminopeptidase. Arch Biochem Biophys 276:305-309.
89. Junaid MA, Wu G, Pullarkat RK. 2000. Purification and characterization of bovine brain lysosomal pepstatin-insensitive proteinase, the gene product deficient in the human late-infantile neuronal ceroid lipofuscinosis. J Neurochem 74:287-294.
90. Kenny AJ. 1977. Proteinases associated with cell membranes. Proteinases in mammalian cells and tissues. Barrett AJ, editor. Amsterdam: Elsevier; pp. 393-344.
91. King MA, Bradshaw S, Chang AH, Pintar JE, Pasernak GW. 2001. Potentiation of opioid analgesia in dopamine-2 receptor knockout mice: Evidence for a tonically active antiopioid system. J Neurosci 21:7788-7792.
92. Knight M, Klee WA. 1978. The relationship between enkephalin degradation and opiate receptor occupancy. J Biol Chem 253:3843-3847.
93. Konig M, Zimmer AM, Steiner H, Holmes PV, Crawley J, et al. 1996. Pain responses, anxiety, and aggression in mice deficient in preenkephalin. Nature 383:535-538.
94. Krieger TK, Hook VYH. 1991. Purification and characterization of a novel thiol protease involved in processing the enkephalin precursor. J Biol Chem 266:8376-8383.
95. Kreiger TK, Mende-Mueller L, Hook VYH. 1992. Prohormone thiol protease and enkephalin precursor processing: Cleavage at dibasic and monobasic sites. J Neurochem 59:26-31.
96. Larrinaga G, Gil J, Meana JJ, Ruiz F, Callado LF, et al. 2005. Aminopeptidase activity in the postmortem brain of human heroin addicts. Neurochem Int 46:213-219.
97. Lentzen H, Palenker J. 1983. Localization of the thiorphansensitive endopeptidase, termed enkephalinase A, on glial cells. FEBS Lett 153:93-97.
98. Llorens C, Cacel G, Swerts J-P, Perdrisot R, Fournie-Zaluski K-C, et al. 1980. Rational design of enkephalinase inhibitor: substrate specificity of enkephalinase studied from inhibitory potency of various dipeptides. Biochem Biophys Res Comm 96:1710-1716.
99. Loh YP, Parish DC, Tuteja R. 1985. Purification and characterization of paired basic residue-specific proopiomelanocortinconverting enzyme form bovine pituitary intermediate lobe secretory vesicles. J Biol Chem 260:7194-7205.
100. Look AT, Ashmun RA, Shapiro LH, Peiper SC. 1989. Human myeloid plasma membrane glycoprotein CD13 (gp150) is identical to aminopeptidase N. J Clin Invest 83:1299-1307.
101. Lucius R, Sievers J, Mentlein R. 1995. Enkephalin metabolism by microglial aminopeptidase N (CD13). J Neurochem 64:1841-1847.
102. Luthi-Carter R, Barczak AK, Speno H, Coyle JT. 1998a. Molecular characterization of human brain N-acetylated α-linked acidic dipeptidase (NAALADase). J Pharmacol Exp Ther 286:1020-1025.
103. Luthi-Carter R, Berger UV, Barczak AK, Enna M, Coyle JT. 1998b. Isolation and expression of a rat brain cDNA encoding glutamate carboxypeptidase II. Proc Natl Acad Sci USA 95:3215-3220.
104. Martignoni E, Blandini F, Petraglia F, Pacchetti C, Bono G, et al. 1992. Cerebrospinal fluid norepinephrine, 3-methoxy-4-hydroxyphenylglycol, and neuropeptide Y levels in Parkinson's disease, multiple system atrophy, and dementia of the Alzheimer type. J Neural Transm Park Dis Dement 4:191-205.
105. Matsumoto A, Itoh K, Matsumoto R. 2000. A novel carboxypeptidase B that processes native βamyloid precursor protein is present in human hippocampus. Eur J Neurosci 12:227-238.
106. McDermott JR, Gibson AM. 1997. Degradation of Alzheimer's βamyloid protein by human and rat brain peptidases: Involvement of insulin-degrading enzyme. Neurochem Res 22:49-56.
107. McLellan S, Dyer SH, Rodriguez G, Hersh LB. 1988. Studies on the tissue distribution of the puromycin-sensitive enkephalin-degrading aminopeptidases. J Neurochem 51:1552-1559.
108. Meyerson BJ, Terenius L. 1977. βendorphin and male sexual behavior. Eur J Pharmacol 42:191-192.
109. Milusheva E, Doda M, Pasztor E, Lajtha A, Sershen H, et al. 1992. Regulatory interactions among axon terminals affecting the release of different transmitters from rat striatal slices under hypoxic and hypoglycemic conditions. J Neurochem 59:946-952.
110. Minnasch P, Yamamoto Y, Ohkubo I, Nishi K. 2003. Demonstration of puromycin-sensitive alanyl aminopeptidase in Alzheimer disease brain. Leg Med (Tokyo). Suppl 1:S285-S287.
111. Mok SS, Evin G, Li QX, Smith AI, Beyreuther K, et al. 1997. A novel metalloprotease in rat brain cleaves the amyloid precursor protein of Alzheimer's disease generating amyloidogenic fragments. Biochemistry 36:156-163.
112. Molleraeu C, Simons MJ, Soulariue P, Liners F, Vassart G, et al. 1996. Structure-tissue distribution and chromosomal localization of the prepronociceptin gene. Proc Natl Acad Sci USA 93:8666-8670.
113. Montes J, Gonzalez Maldonado R, Peinado JM. 1998. Alanylaminopeptidase activity decrease in cerebrospinal fluid of Alzheimer patients. Dement Geriatr Cogn Disord 9:44-49.
114. Morley JE. 1980. The neuroendocrine control of appetite: the role of the endogenous opiates, cholecystokinin, TRH, g-amino-butyric-acid. Life Sci 27:355-368.
115. Morley JE. 1981. The endocrinology of the opiates and opioid peptides. Metabolism 30:195-209.
116. Nakanish S, Inoue A, Kita T, Nakamura M, Chang ACY, et al. 1979. Nucleotide sequence of cloned cDNA for bovine corticotropin-βlipotropin precursor. Nature 278:423-424.
117. Neidle A, Zhu M-X, Hui K-S. Purification and characterization of a novel bestatin-insensitive aminoenkephalinase from rat brain cytosol. (MS in preparation)
118. Neuser D, Lesch KP, Stasch JP, Przuntek H. 1984. βendorphin-, leucine enkephalin-, and methionine enkephalin-like immunoreactivity in human cerebrospinal fluid. Simultaneous determination and relation to neurological disorders. Eur Neurol 23:73-81.
119. Noble F, Roques βP. 1992. Selective opioid agonists and inhibitors of enkephalin degradation enzymes: Pharmacological and clinical values. C R Seances Soc Biol Fil 186:37-60.
120. Noda Y, Mamiya T, Manabe T, Nishi M, Takeshima H, et al. 2000. Role of nociceptin systems in learning and memory. Peptides 7:1063-1069.
121. Nothacker HP, Reinschied RK, Mansour A, Henningsen RA, Ardati A, et al. 1996. Primary structure and tissue distribution of the orphanin FQ precursor. Proc Natl Acad Sci USA 93:8677-8682.
122. Okuda M, Arakawa K. 1985. Potent inhibition of angiotensinconverting enzyme by [des-Pro3]-bradykinin or "converstatin" in comparison with captopril. J Biochem (Tokyo) 98:621-628.
123. Orlowski M. 1983. Proteinases. Handbook of neurochemistry, Vol. 4. Lajtha A, editor. 2nd Ed. NY: Plenum; pp. 21-66.
124. Osada T, Ikegami S, Takiguchi-Hayashi K, Yamazaki Y, Katoh-Fukui Y, et al. 1999. Increased anxiety and impaired pain response in puromycin-sensitive aminopeptidase gene-deficient mice obtained by a mouse gene-trap method. J Neurosci 19:6068-6078.
125. Palacios JM, Rigo M, Chinaglia G, Probst A. 1990. Reduced density of striatal somatostatin receptors in Huntington's chorea. Brain Res 522:342-346.
126. Pasquini F, Bochet P, Garbay-Jaureguiberry C, Roques βP, Rossier J, et al. 1992. Electron microscopic localization of photoaffinity-labeled d opioid receptors in the neostriatum of the rat. J Comp Neurol 326:229-244.
127. Patey G, De La Baume S, Schwartz J-C, Gros C, Roques βP, et al. 1981. Selective protection of methionine enkephalin release from brain slices by enkephalinase inhibition. Science 212:1153-1155.
128. Perich RB, Jackson B, Rogerson F, Mendelsohn FA, Paxton D, et al. 1992. Two binding sites on angiotensin-converting enzyme: Evidence from radioligand-binding studies. Mol Pharmacol 42:286-293.
129. Petersson S, Lavebratt C, Schalling M, Hokfelt T. 2000. Expression of cholecystokinin, enkephalin, galanin, and neuropeptide Y is markedly changed in the brain of the megencephaly mouse. Neuroscience 100:297-317.
130. Petersson S, Sandberg Nordqvist A, Schalling M, Lavebratt C. 1999. The megencephaly mouse has disturbances in the insulin-like growth factor (IGF) system. Brain Res Mol Brain Res 72:80-88.
131. Pickering DS, Krishna MV, Miller DC, Chan WW. 1985. Structural requirements for specific inhibition of microsomal aminopeptidase by mercaptoamines. Arch Biochem Biophys 239:368-374.
132. Przewlocki R, Przewlocka B. 2001. Opioid in chronic pain. Eur J Pharmacol 429:79-91.
133. Rapaka RS. 1986. Research topics in the medicinal chemistry and molecular pharmacology of opioid peptide-present and future. Life Sci 39:1825-1843.
134. Razak K, Newland AC. 1992. Induction of CD13 expression on fresh myeloid leukaemia: Correlation of CD13 expression with aminopeptidase-N activity. Leuk Res 16:625-630.
135. Reid AC, Morton JJ. 1982. Arginine-vasopressin levels in cerebrospinal fluid in neurological disease. J Neurol Sci 54:295-301.
136. Reinscheid RK, Nothacker HP, Bourson A, Ardat A, Henningsen RA, et al. 1995. Orphanin FQ: a neuropeptide that activates an opioid-like G protein-coupled receptor. Science 270:792-794.
137. Rojas C, Thomas AG, Majer P, Tsukamoto T, Lu XM, et al. 2003. Glutamate carboxypeptidase II inhibition as a novel therapeutic target. Adv Exp Med Biol 524:205-213.
138. Rose C, Vargas F, Facchinetti P, Bourgeat P, Bambal RB, et al. 1996. Characterization and inhibition of a cholecystokinininactivating serine peptidase. Nature 380:403-409.
139. Sagar SM, Beal MF, Marshall PE, Landis DM, Martin JB. 1984. Implications of neuropeptides in neurological diseases. Peptides 5:255-262.
140. Sankaran K, Hindmarsh KW, Watson VG. 1984. Hypoxic-ischemic encephalopathy and plasma βendorphin. Dev Pharmacol Ther 7:377-383.
141. Sato M, Yanagisawa K, Kondo H, Wakamatsu N, Tani N, et al. 1991. Treatment of neurological complications in isolated ACTH deficiency by glucocorticoid replacement. Jpn J Med 30:243-6.
142. Schiller MR, Kohn AB, Mende-Mueller L, Miller K, Hook VYH. 1996. Expression of recombinant proneuropeptide Y, proopiomelanocortin, and proenkephalin: Relative processing by "prohormone thiol protease" (PTP). FEBS Lett 382:6-10.
143. Schiller MR, Mende-Mueller L, Moran K, Meng M, Miller KW, et al. 1995. Prohormone thiol protease (PTP) processing of recombinant proenkephalin. Biochemistry 34:7988-7995.
144. Schullek JR, Wilson IB. 1988. The binding of zinc to angiotensin- converting enzyme. Arch Biochem Biophys 265:346-350.
145. Schwartz J-C, Costentin J, Lecomte J-M. 1985. Pharmacology of enkephalinase inhibitors. Trends Pharmacol Sci 6:472-476.
146. Seidah NG, Mbikay M, Marcinkiewicz M, Chretien M. 1998. The mammalian precursor convertases; paralogs of the subtilisin/kexin family of calcium-dependent serine proteinases. Proteolytic and cellular mechanisms in prohormone and proprotein processing. Hook VYH, editor. Austin, TX: Landes Co., pp 49-68.
147. Shannon JD, Baramova EN, Bjarnason JB, Fox JW. 1989. Amino acid sequence of a Crotalus atrox venom metalloproteinase which cleaves type IV collagen and gelatin. J Biol Chem 264:11575-11583.
148. Shaw SG, Cook WF. 1978. Localization and characterisation of aminopeptidase in the CNS and the hydrolysis of enkephalin. Nature 274:816-817.
149. Silva WI, Benitez K, Ocasio J, Martinez L, Rosario N. 1995. Neuropeptide-like immunoreactivities and carboxypeptide H activity associated with bovine brain clathrin coated vesicles. Neuropeptides 28:341-349.
150. Solhonne B, Gros C, Pollard H, Schwartz J-C. 1987. Major localization of aminopeptidase M in rat brain microvessels. Neuroscience 22:225-232.
151. Sorensen PS, Gjerris A, Hammer M. 1985. Cerebrospinal fluid vasopressin in neurological and psychiatric disorders. J Neurol Neurosurg Psychiatry 48:50-7.
152. Soubrier F, Alhenc-Gelas F, Hubert C, Allegrini J, John M, et al. 1988. Two putative active centers in human angiotensin I-converting enzyme revealed by molecular cloning. Proc Natl Acad Sci USA 85:9386-9390.
153. Stanton A. 2003 Therapeutic potential of renin inhibitors in the management of cardiovascular disorders. AM J Cardiovasc Drugs 3:389-94.
154. Steiner DF, Smeekens SP, Ohagi S, Chan SJ. 1992. The new enzymology of precursor processing endoproteases. J Biol Chem 267:23435-23438.
155. Sundquist J, Forsling ML, Olsson JE, Akerlund M. 1983. Cerebrospinal fluid arginine vasopressin in degenerative disorders and other neurological diseases. J Neurol Neurosurg Psychiatry 46:14-7.
156. Suzuki S, Chuang LF, Doi RH, Bidlack JM, Chuang RY. 2001. k-Opioid receptors on lymphocytes of a human lymphocytic cell line: Morphine-induced upregulation as evidenced by competitive RT-PCR and indirect immunofluorescence. Int Immunopharmacol 1:1733-1742.
157. Tanioka T, Hattori A, Masuda S, Nomura Y, Nakayama H, Mizutani S, Tsujimoto M. 2003. Human leukocytederived arginine aminopeptidase: The third member of the oxytocinase subfamily of aminopeptidases. J Biol Chem 278, 32275-32283.
158. Tezaosudusm N, Noctor S, Kannan R, Krieger TK, Mende-Mueller L, et al. 1995. Stimulation of "prohormone thiol protease" (PTP) and (Met) enkephalin for forskolin: Blockade of elevated (Met) enkephalin by cysteine protease inhibitor of PTP. J Biol Chem 270:13285-13290.
159. Thomas AG, Olkowski JL, Slusher BS. 2001. Neuroprotection afforded by NAAG and NAALADase inhibition requires glial cells and metabotropic glutamate receptor activation. Eur J Pharmacol 426:35-38.
160. Thompson MW, Hersh LB. 2003. Analysis of conserved residues of the human puromycin-sensitive aminopeptidase. Peptides 24:1359-1365.
161. Thompson MW, Govindaswami M, Hersh LB. 2003. Mutation of active site residues of the puromycin-sensitive aminopeptidase: Conversion of the enzyme into a catalytically inactive binding protein. Arch Biochem Biophys 413:236-242.
162. Thompson MW, Tobler A, Fontana A, Hersh LB. 1999. Cloning and analysis of the gene for the human puromycinsensitive aminopeptidase. Biochem Biophys Res Commun 258:234-240.
163. Thorsett ED, Wyvratt MJ. 1987. Inhibition of zinc peptidases that hydrolyse neuropeptides. Neuropeptides and their peptidases. Turner AJ, editor. Ellis-Horwood: Chichester; pp 229-292.
164. Tieku S, Hooper NM. 1992. Inhibition of aminopeptidases N, A, and W. Biochem Pharmacol 44:1725-1730
165. Tobler AR, Constam DB, Schmitt-Graff A, Malipiero U, Schlapbach R, et al. 1997. Cloning of the human puromycin-sensitive aminopeptidase and evidence for expression in neuron. J Neurochem 68:889-897.
166. Tomkinson B. 1999. Tripeptidyl peptidases: Enzymes that count. Trends Biochem Sci 24:355-359.
167. Turner AJ, Barnes K. 1995. Distribution and roles of endopeptidase 24.11. Peptidases and neuropeptide processing. Smith AI, editor. NY: Academic Press; pp. 344-362.
168. Turner AJ, Isaac RE, Coates D. 2001. The neprilysin (NEP) family of zinc metalloendopeptidases: Genomics and function. Bioessays 23:261-269.
169. Turner AJ, Murphy LJ, Medeios MS, Barnes K. 1996. Endopeptidase 24.11 (neprilysin) and relatives:20 years on. Adv Exp Med Biol 389:141-148.
170. Umezawa H. 1972. Enzyme inhibitors of microbial origin. Tokyo: University of Tokyo Press.
171. Umezawa H, Aoyagi T. 1977. Activities of proteinase inhibitors of microbial origin. Proteinases in mammalian cells and tissues proteinases in mammalian cells and tissues. Barrett AJ, editor. Amsterdam: Elsevier; pp. 636-662.
172. Ungar A, Phillips JH. 1983. Regulation of the adrenal medulla. Physiol Rev 63:787-843.
173. Van Amsterdam JGC, Van Buuren KJH, Blad MWM, Soudijn W. 1987. Synthesis of enkephalinase B inhibitors and their activity on isolated enkephalin-degrading enzymes. Eur J Pharmacol 135:411-418.
174. Vecsei L, Widerlov E. 1988. Brain and CSF somatostatin concentrations in patients with psychiatric or neurological illness. An overview. Acta Psychiatr Scand 78:657-667.
175. Vecsei L, Widerlov E. 1990. Preclinical and clinical studies with somatostatin related to the central nervous system. Acta Psychiatr Scand 14:473-502.
176. Wahlestedt C, Ekman R, Widerlov E. 1989. Neuropeptide Y (NPY) and the central nervous system: Distribution effects and possible relationship to neurological and psychiatric disorders. Prog Neuropsychopharmacol Biol Psychiatry 13:31-54.
177. Wang JB, Imai Y, Eppler CM, Gregor P, Spivak CE, et al. 1993. m opiate receptor: cDNA cloning and expression. Proc Natl Acad Sci USA 90:10230-10234.
178. Warburton MJ, Bernardini F. 2002. Tripeptidyl peptidase-I is essential for the degradation of sulfated cholecystokinin-8 (CCK-8S) by mouse brain lysosomes. Neurosci Lett 331:99-102.
179. Waters SM, Davis TP. 1995. Alterations of substance P metabolism and neuropeptidases in Alzheimer's disease. J Gerontol A Biol Sci Med Sci 50:B315-B319.
180. Waters SM, Davis TP. 1997. Alterations of peptide metabolism and neuropeptidase activity in senile dementia of the Alzheimer's type. Ann N Y Acad Sci 814:30-39.
181. Wei L, Alhenc-Gelas F, Corvol P, Clauser E. 1991. The two homologous domains of human angiotensin I-converting enzyme are both catalytically active. J Biol Chem 266:9002-9008.
182. Wei L, Clauser E, Alhenc-Gelas F, Corvol P. 1992. The two homologous domains of human angiotensin I-converting enzyme interact differently with competitive inhibitors. J Biol Chem 267:13398-13405.
183. Wei S, Feng Y, Kalinina E, Fricker LD. 2003. Neuropeptideprocessing carboxypeptidases. Life Sci 736:655-662.
184. Wei S, Segura S, Vendrell J, Aviles FX, Lanoue E, Day R, Feng Y, Fricker LD. 2002. Identification and characterization of three members of the human metallocarboxypeptidase gene family. J Biol Chem 277:14954-64.
185. Wilk S, Friedman TC, Kline TB. 1985. Pyroglutamyl diazomethyl ketone: Potent inhibitor of mammalian pyroglutamyl peptide hydrolase. Biochem Biophys Res Comm 130:662-668.
186. Winkler H, Sietzen M, Schober M. 1987. The life cycle of catecholamine-storing vesicles. Ann N YAcad Sci 493:3-19.
187. Witkin JM, Gasior M, Schad C, Zapata A, Shippenberg T, et al. 2002. NAALADase (GCP II) inhibition prevents cocaine-kindled seizures. Neuropharmacology 43:348-356.
188. Wujek P, Kida E, Walus M, Wisniewski KE, Golabek AA. 2004. N-glycosylation is crucial for folding, trafficking, and stability of human tripeptidyl peptidase I. J Biol Chem 279:12827-12839.
189. Yamamoto M, Chikuma T, Yajima R, Hirano H, Yamamoto Y, et al. 2002. Axonal transport of puromycin-sensitive aminopeptidase in rat sciatic nerves. Neurosci Res 42:133-140.
190. Yamin R, Malgeri EG, Sloane JA, McGraw WT, Abraham CR. 1999. Metalloendopeptidase EC 3.4.24.15 is necessary for Alzheimer's amyloid-β peptide degradation. J Biol Chem 274:18777-18784.
191. Yasothornsrikul S, Aaron W, Toneff T, Hook VYH. 1999. Evidence for the proenkephalin-processing enzyme "prohormone thiol protease" (PTP) as a multicatalytic cysteine protease complex; activation by glutathione localization to secretory vesicles. Biochemistry 38:7421-7430.
192. Yasothornsrikul S, Greenbaum D, Medzihradszky KF, Toneff T, Bundey R, et al. 2003. Cathepsin L in secretory vesicles functions as a prohormone-processing enzyme for production of the enkephalin peptide neurotransmitter. Proc Natl Acad Sci USA 100:9590-9595.
193. Yasothornsrikul S, Toneff T, Hook VYH. 1998. Arginine and lysine aminopeptidase activities in neurosecretory vesicles of adrenal medulla: Relevance to prohormone processing. J Neurochem 70:153-163.
194. Yoshikawa K, Williams C, Sabol SL. 1984. Rat brain preproenkephalin mRNA, cDNA cloning, primary structure, and distribution in the central nervous system. J Biol Chem 259:14301-14308.
195. Yourick DL, Koenig ML, Durden AV, Long JB. 2003. N- acetylaspartylglutamate and β-NAAG protect against injury induced by NMDA and hypoxia in primary spinal cord cultures. Brain Res 991:56-64.
196. Zhang A-Z, Yang H-Y, Costa E. 1982. Nociception, enkephalin content, and dipeptidyl carboxypeptidase activity in brain of mice treated with exopeptidase inhibitors. Neuropharmacol 21:625-630.